Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma.

Abstract

We studied the effects of a new topical angiotensin converting enzyme inhibitor, SCH 33861, in lowering intraocular pressure in 20 patients with ocular hypertension or primary open-angle glaucoma. In a double-masked, four-way crossover study with placebo and timolol, SCH 33861 was well tolerated and effective in lowering intraocular pressure. The magnitude of the drug's effect in lowering intraocular pressure was less than that of timolol 0.5%.

• Authors: W H Constad, P Fiore, C Samson, A A Cinotti
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 105 Issue 6 Pg. 674-7 (Jun 15 1988) ISSN: 0002-9394 [Print] United States
• PMID: 3287943 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Phenylbutyrates
• Spiro Compounds
• Timolol
• SCH 33861

Topics

• Adult
• Aged
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Clinical Trials as Topic
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure
• Male
• Middle Aged
• Ocular Hypertension (drug therapy, physiopathology)
• Phenylbutyrates (adverse effects, therapeutic use)
• Pulse (drug effects)
• Spiro Compounds (adverse effects, therapeutic use)
• Time Factors
• Timolol (therapeutic use)